Prolactin release by vasoactive intestinal polypeptide in rats.
Synthetic vasoactive intestinal polypeptide (VIP) administered either intraventricularly or iv caused a significant and dose-related increase in plasma PRL levels in urethane-anesthetized rats. The administration of naloxone, an opiate receptor antagonist, significantly blunted the plasma PRL response to VIP. Increases in plasma PRL induced by VIP were also significantly suppressed by L-dopa, a precursor of dopamine, whereas pilocarpine, a cholinergic agonist, diphenhydramine, a histamine antagonist, and cyproheptadine, an antiserotoninergic agent, did not affect the plasma PRL response to VIP. In in vitro experiments, VIP alone did not stimulate PRL release from cultured pituitary cells, but it significantly attenuated the inhibitory action of dopamine, which was not blocked by naloxone. These results suggest that VIP stimulates rat PRL secretion, at least in part, through activation of an opiate receptor in the central nervous system and by blocking the inhibitory action of a dopaminergic mechanism at the pituitary level.
D000818:Animals; D003533:Cyproheptadine / Q000494:pharmacology; D004155:Diphenhydramine / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D051381:Rats; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D005768:Gastrointestinal Hormones; D010862:Pilocarpine; D003533:Cyproheptadine; D009270:Naloxone; D014660:Vasoactive Intestinal Peptide; D004155:Diphenhydramine; D011388:Prolactin; D004298:Dopamine